TY - JOUR
T1 - Definition of fatty acid transport protein-2 (FATP2) structure facilitates identification of small molecule inhibitors for the treatment of diabetic complications
AU - Kumar, Mukesh
AU - Gaivin, Robert J.
AU - Khan, Shenaz
AU - Fedorov, Yuriy
AU - Adams, Drew J.
AU - Zhao, Weiyang
AU - Lee, Hsueh Yun
AU - Dai, Xinghong
AU - Dealwis, Chris G.
AU - Schelling, Jeffrey R.
N1 - Funding Information:
This work was supported by NIH grant R01 DK067528 (to JRS).
Publisher Copyright:
© 2023 Elsevier B.V.
PY - 2023/7/31
Y1 - 2023/7/31
N2 - Diabetes is a major public health problem due to morbidity and mortality associated with end organ complications. Uptake of fatty acids by Fatty Acid Transport Protein-2 (FATP2) contributes to hyperglycemia, diabetic kidney and liver disease pathogenesis. Because FATP2 structure is unknown, a homology model was constructed, validated by AlphaFold2 prediction and site-directed mutagenesis, and then used to conduct a virtual drug discovery screen. In silico similarity searches to two low-micromolar IC50 FATP2 inhibitors, followed by docking and pharmacokinetics predictions, narrowed a diverse 800,000 compound library to 23 hits. These candidates were further evaluated for inhibition of FATP2-dependent fatty acid uptake and apoptosis in cells. Two compounds demonstrated nanomolar IC50, and were further characterized by molecular dynamic simulations. The results highlight the feasibility of combining a homology model with in silico and in vitro screening, to economically identify high affinity inhibitors of FATP2, as potential treatment for diabetes and its complications.
AB - Diabetes is a major public health problem due to morbidity and mortality associated with end organ complications. Uptake of fatty acids by Fatty Acid Transport Protein-2 (FATP2) contributes to hyperglycemia, diabetic kidney and liver disease pathogenesis. Because FATP2 structure is unknown, a homology model was constructed, validated by AlphaFold2 prediction and site-directed mutagenesis, and then used to conduct a virtual drug discovery screen. In silico similarity searches to two low-micromolar IC50 FATP2 inhibitors, followed by docking and pharmacokinetics predictions, narrowed a diverse 800,000 compound library to 23 hits. These candidates were further evaluated for inhibition of FATP2-dependent fatty acid uptake and apoptosis in cells. Two compounds demonstrated nanomolar IC50, and were further characterized by molecular dynamic simulations. The results highlight the feasibility of combining a homology model with in silico and in vitro screening, to economically identify high affinity inhibitors of FATP2, as potential treatment for diabetes and its complications.
KW - Drug discovery
KW - FATP2
KW - Molecular dynamics simulation
UR - http://www.scopus.com/inward/record.url?scp=85162861861&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85162861861&partnerID=8YFLogxK
U2 - 10.1016/j.ijbiomac.2023.125328
DO - 10.1016/j.ijbiomac.2023.125328
M3 - Article
C2 - 37307967
AN - SCOPUS:85162861861
SN - 0141-8130
VL - 244
JO - International Journal of Biological Macromolecules
JF - International Journal of Biological Macromolecules
M1 - 125328
ER -